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Introduction: Although immune dysfunction plays a role in the pathogenesis of systemic sclerosis (SSc), involvement
of T helper 17 (Th17) and T regulatory (Treg) cells remains unclear. We aimed to investigate the presence of Th17 and
Treg cells in SSc patients and the role of Th17 cells in collagen production in SSc fibroblasts.
Methods: We analyzed inflammatory cell profiles in the skin of 13 SSc patients by immunohistochemistry, the
percentage of Th17 and Treg cells in peripheral blood mononuclear cells (PBMCs) of 45 SSc patients and 24 healthy
controls by flow cytometry, gene expression in PBMCs by real-time reverse transcription-polymerase chain reaction and
interleukin-17 (IL-17) in sera and culture supernatants by enzyme-linked immunosorbent assay. We also investigated
the effect of Th17 cell-derived IL-17 on fibroblast growth and collagen production.
Results: Infiltration of inflammatory cells including IL-17+ and Foxp3+ lymphocytes was detected in the skin of patients
with early SSc. The percentages of circulating Th17 cells and IL-17 production were elevated in samples from patients
with active SSc, whereas the percentage of circulating Treg cells was not affected. The number of Th17 cells was closely
related to disease activity. IL-17 from SSc patients promoted fibroblast growth and collagen production, whereas IL-17
neutralizing antibody effectively blocked collagen production.
Conclusion: SSc progression might be linked to expansion of circulating Th17 cells and increased infiltration of
IL-17+ cells in skin. Th17-derived IL-17 is involved in fibroblast growth and collagen production. IL-17 blocking
antibody may be a useful tool for intervention in the fibrotic course of SSc.Introduction
Systemic sclerosis (SSc) is a complex inflammatory auto-
immune disease characterized by excessive deposition of
collagen that leads to fibrosis of multiple organs, inclu-
ding the skin, lungs, heart, and gastrointestinal tract,
and is often associated with widespread vasculopathy
and immunologic abnormalities [1].
A unique feature of SSc that distinguishes it from other
fibrotic disorders is that autoimmunity and vasculopathy
characteristically precede fibrosis. Although immunomo-
dulatory drugs have been used extensively in the treat-
ment of SSc, to date, no therapy has been able to reverse
the progression of tissue fibrosis or substantially to modify* Correspondence: li.ming@zs-hospital.sh.cn
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reproduction in any medium, provided the orthe natural progression of the disease. This is mainly be-
cause the mechanisms responsible for the initiation and
progression of the disease have not been clearly identified.
Growing evidence suggests that T-cell proliferation and
cytokine secretion play a major role in the pathogenesis of
SSc [2-4], suggesting that this condition could be asso-
ciated with a general defect in the control of T-cell activa-
tion [3]. Recently, a subset of T-helper cells was described
and named T helper 17 (Th17) cells, based on their pro-
duction of interleukin (IL)-17A, IL-17F, and IL-22 [5,6].
IL-17 concentration was reported to be elevated in the
serum of SSc patients [7,8]. This finding was further con-
firmed in more recent studies, which reported drastically
increased proportions of Th17 cells in SSc patients [9-11].
Our previous study showed that Th17 cells are expanded
in systemic lupus erythematosus (SLE) patients, and Th17
cell-derived IL-17 is related to recruitment of inflamma-
tory cells to vascular endothelial cells [12]; however, thed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clear. Naturally occurring CD4 regulatory T (Treg) cells
maintain immune balance and control the inflammatory
injuries [13,14]. It has been suggested that Th17 and Treg
cells are produced in a reciprocal manner, depending on
the levels of potentially proinflammatory or antiinflam-
matory cytokines and activation of specific transcription
factors [15,16]. Thus, we hypothesized that altered cyto-
kine profiles in SSc patients might result in an imbalance
of Th17/Treg cells, and might be responsible for the
prominent features of SSc, such as fibroblast proliferation
and endothelium injury [2,17].
Here, we first demonstrated increased IL-17+ and Foxp3+
lymphocyte infiltration in the lesions of patients with early
SSc. In detailed studies of circulating Th17 and Treg cells
in 45 SSc patients, we showed that Th17 cells exhibited
global expansion in peripheral blood rather than redi-
stribution in vivo, and this expansion of Th17 cells was re-
lated to disease activity but was not correlated with Treg
cell depletion during disease flare. Further studies demon-
strated that IL-17 derived from patients with active SSc
promoted fibroblast growth and collagen production, and
neutralization of IL-17 could alleviate the production of
collagen. These data suggest that the pathophysiology of
SSc might be linked to the expansion of Th17 cells, and
that Th17-derived IL-17 may play a key role in the fibrotic
course of SSc.
Methods
SSc patients and healthy controls
This study was approved by the Ethical Committee of
Zhongshan Hospital, Fudan University (Shanghai, People’s
Republic of China). All SSc patients were referred to the
Department of Dermatology at Zhongshan Hospital and
all provided informed consent. Forty-five consecutive
adult patients (36 women and nine men, mean age 50.9 ±
7.2 years) who met the American College of Rheuma-
tology criteria for the classification of SSc were included
in the study [18]. Among these, 20 patients were classified
as having limited cutaneous SSc (lSSc), and 25, as having
diffuse cutaneous SSc (dSSc), according to the system pro-
posed by Le Roy et al. [19]. Disease activity was assessed
by using the criteria proposed by Valentini et al. [20], in
which evaluation of clinical and laboratory factors results
in a score ranging from 0 to 10 (0 represents no disease
activity, and 10 represents maximal activity) [20]. Thirteen
patients (nine women and four men, mean age, 48.4 ±
7.2 years) with a score ≥3 were classified as the active
SSc group. The stable SSc group comprised 32 patients
(27 women and five men, mean age, 51.9 ± 14.2 years)
with score a <3. SSc patients were treated with prednis-
one, or cyclophosphamide + prednisone.
For the control group, 24 age- and sex-matched
healthy individuals (18 women and six men, mean age,50 ± 9.2 years) were enrolled after providing informed
consent.
For histochemistry analysis, skin tissue was obtained
from skin biopsies of 13 SSc patients (the location of
skin biopsies is the flexure side of the forearm). Disease
stage was defined as proposed by Steen and Medsger:
early lSSc, disease duration <5 years; late lSSc, disease
duration ≥5 years; early dSSc, disease duration <3 years;
late dSSc, disease duration ≥3 years; disease duration
was from first non-Raynaud symptoms [21,22]. Eight pa-
tients were classified as early SSc (12 ± 7.0 months), five
as late SSc (45 ± 8.8 months), 12 were classified as dSSc,
and one as lSSc. Four age- and sex-matched healthy tis-
sue samples were obtained with informed consent (three
skin biopsies from healthy donors and one tissue from
orthopedic surgery).
Immunohistochemistry
Tissues were processed and embedded in paraffin by using
routine methods. Tissue blocks were serially sectioned to
obtain consecutive levels. Sections were stained with
hematoxylin and eosin, and immunohistochemistry was
performed as previously described [12] by using antibodies
to CD3, CD4, CD8, CD20, CD68, IL-17, and Foxp3 (all
from Abcam, Cambridge, MA, USA). Immunohistoche-
mical staining was assessed by two independent patholo-
gists without knowledge of patient characteristics. The
positive cells in per surface were counted under × 400
magnification, and five randomly selected independent
microscopic fields were counted for each sample to ensure
that the data were representative and homogeneous.
Flow cytometry
For detection of Treg cells, PBMCs were stained with
fluorescein isothiocyanate (FITC)-conjugated anti-CD4,
phycoerythrin (PE)-Cy5-conjugated anti-CD25, and PE-
conjugated anti-CD127 (BD Pharmingen, San Jose, CA,
USA) according to the manufacturer’s protocol. We
gated first on CD4+ T cells and then on CD25+CD127-
Treg cells, as previously described [12]. After staining,
cells were washed twice and resuspended in FACS solu-
tion (phosphate-buffered saline (PBS) with 0.5% bovine
serum albumin and 0.02% sodium azide), fixed in PBS
containing 1% paraformaldehyde, and analyzed the same
day in a FACS-Calibur (BD-Bioscience) followed by ana-
lysis with FlowJo (Tree Star).
For detection of Th17 cells, PBMCs were incubated
for 4 to 5 hours with 50 ng/ml phorbol 12-myristate
13-acetate (PMA) and 750 ng/ml ionomycin (PI) in the
presence of 20 μg/ml Brefeldin A (Sigma-Aldrich, St.
Louis, MO, USA) in a tissue-culture incubator at 37°C.
Surface staining with PE-Cy5-conjugated anti-CD3 and
FITC-conjugated anti-CD8 (BD Pharmingen) was per-
formed for 15 minutes, followed by resuspension in
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CA, USA), according to the manufacturer’s instructions.
Intracellular staining of PE-conjugated anti-IL-17 or iso-
type control was performed according to the manufac-
turer’s protocol (eBioscience, San Diego, CA, USA). For
detection of Th17 cells, we first gated on CD3+ T cells,
and analyzed CD8-IL-17+ T cells in a CD3+ gate, as pre-
viously described [12].
Fibroblast isolation, culture, and stimulation
Fibroblasts producing high levels of collagen were
isolated from the skin of SSc patients according to our
previous modified limiting-dilution method [23]. Isolated
fibroblasts were cultured in the presence of 20 ng/ml
IL-17 (eBioscience) for the indicated number of days,
and the growth of fibroblasts was analyzed by 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. For gene-expression experiments, fibroblasts
were cultured in different doses of IL-17 for 48 hours, and
collagen 1 and collagen 3 gene expression was analyzed by
real-time reverse transcription-polymerase chain reaction
(RT-PCR).
To determine the effect of secreted IL-17 on collagen
production, PBMCs from patients with active SSc were
incubated for 4 to 5 hours with PI (Sigma-Aldrich), and
supernatants were collected for later use. Fibroblasts
isolated from the skin of SSc patients were cultured for
48 hours, and the culture media was replaced with
Dulbecco modified Eagle medium (DMEM; Hyclone,
Logan, UT, USA) containing 20% supernatant from the
stimulated active SSc PBMC culture, and the cultures
were incubated for a further 48 hours. Antibody to IL-17
(eBioscience) was added to some cultures to a final con-
centration of 20 μg/ml. Culture media with the same
doses of PI was used as a vehicle control. Collagen gene
expression in fibroblasts was analyzed with real-time
RT-PCR, and collagen secretion was analyzed by enzyme-
linked immunosorbent assay (ELISA).
In similar experiments, isolated CD4+CD161+CD196+
Th17 cells [24,25] (eBioscience) were incubated for 4 to
5 hours with PI, and the supernatants were collected.
Fibroblasts were cultured for 48 hours, and the culture
media was replaced with DMEM (Hyclone) containing
20% supernatant from Th17 cells (4 × 105 cells) from
patients with active SSc or healthy controls. Antibody to
IL-17 was added to some cultures to a final concentra-
tion of 20 μg/ml. After incubation for another 48 hours,
collagen secretion was analyzed with ELISA.
ELISA
Sera were collected from SSc patients and healthy controls
and frozen at -80°C until needed. Serum concentrations of
IL-17 were determined with ELISA (R&D, Minneapolis,
MN, USA). In some experiments, isolated PBMCs werecultured and stimulated with PI (Sigma-Aldrich) for
5 hours before measurement of IL-17 in the supernatants.
Analysis of cytokine and transcription factor mRNA
expression
Total RNA was purified with Trizol reagent (Invitrogen).
cDNAs were synthesized by using ReverTra Ace-α- Kit
(Toyobo), and mRNA expression was determined by using
a SYBR green kit (Toyobo). The 2-ΔΔCt method was used
to normalize transcription to β-actin and to calculate the
fold induction relative to controls. The following primer
pairs were used: Hum 18S, forward GCCCGAAGCGTT
TACTTTGA and reverse TCCATTATTCCTAGCTGC
GGTATC; Hum Foxp3, forward GAAACAGCACAT
TCCCAGAGTTC and reverse ATGGCCCAGCGGAT
GAG; Hum retinoic acid-related orphan receptor-gamma
t (RORγt), forward TGAGAAGGACAGGGAGCCAA and
reverse CCACAGATTTTGCAAGGGATCA; Hum IL-17,
forward CAACCGATCCACCTCACCTT and reverse GG
CACTTTGCCTCCCAGAT; Hum COL1, forward GTTG
TGCGATGACGTGATCTGTGA and reverse TTCTTGG




Results were expressed as mean ± standard deviation.
Statistical significance was determined by analysis of
variance for comparisons of multiple means followed by
the Bonferroni post hoc test or the Student t test and
the Mann-Whitney U test. Correlations were deter-
mined with Spearman ranking.
Results
Inflammatory cell profiles in skin of SSc patients
Previous histologic analysis of skin from SSc patients
showed small pericapillary lymphocytic infiltrates [3];
however, it is not clear whether a specific immune re-
sponse signature of the skin microenvironment occurs in
SSc or whether the skin inflammation is governed by a
predominantly immune response. In this study, among
the 13 SSc patients enrolled, eight were classified as early
SSc (12 ± 7.0 months), and five, as late SSc (45 ±
8.8 months). CD3+, CD4+, CD8+, CD20+, and CD68+ cells
were examined with immunohistochemical staining of
consecutive serial sections. Our data showed complex in-
flammatory cell infiltration but no predominant subsets of
inflammatory cells. CD3+, CD4+, CD8+, and CD68+ cells
were detected in both superficial and deep dermis of
involved skin from patients with early SSc, with CD20+
cells mainly infiltrating pericapillary regions in the deep
dermis (Figure 1A, B). The number of infiltrated cells was
significantly decreased in skin from late SSc patients com-
pared with early SSc (Figure 1C through F).
Figure 1 The profile of inflammatory cells in the skin of SSc patients. (A) Hematoxylin and eosin (H&E) staining of consecutive serial sections
showing typical pathologic changes of SSc (left panel); lymphocyte infiltration confirmed by CD3, CD4, CD8, CD20, and CD68 immunohistochemical
staining in superficial dermis of patients with early SSc (right panels). (B) H&E staining (Left panel); lymphocyte infiltration confirmed by CD3, CD4, CD8,
CD20, and CD68 immunohistochemical staining in superficial dermis of late SSc patients (right panels). (C) H&E staining (left panel); lymphocyte
infiltration confirmed by CD3, CD4, CD8, CD20, and CD68 immunohistochemical staining in deep dermis of early SSc patients (right panels). (D) H&E
staining (left panel); lymphocyte infiltration confirmed by CD3, CD4, CD8, CD20, and CD68 immunohistochemical staining in deep dermis of patients
with late SSc (right panels). (E) Counts of CD3+, CD4+, CD8+, CD20+, and CD68+ lymphocytes in superficial dermis of skin (early SSc patients, n = 8; late
SSc patients n = 5). (F) Counts of CD3+, CD4+, CD8+, CD20+, and CD68+ lymphocytes in deep dermis of skin (early SSc patients, n = 8; late SSc patients,
n = 5). The positive cells in the surface were counted under × 400 magnification, and five randomly selected independent microscopic fields were
counted for each sample to ensure that the data were representative and homogeneous. Scale bar, 100 μm.
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filtration is involved in the course of early SSc and that
the inflammation reaction decreases in later stages of
disease.
Increased infiltration of IL-17+ and Foxp3+ lymphocytes in
the skin of patients with early SSc
We analyzed the infiltration of IL-17+ and Foxp3+ cells
in skin biopsy specimens from patients with SSc and
healthy controls by using immunohistochemistry. The
infiltration of IL-17+ cells, expressed as the number of
cells showing superficial and deep dermal infiltration
under × 400 magnification, was significantly increasedin skin from lesions of early SSc patients (superficial der-
mis: 7.5 ± 1.6 cells; deep dermis: 9.1 ± 1.8 cells) com-
pared with late SSc patients (superficial dermis: 1.2 ± 0.8
cells; deep dermis: 1.0 ± 0.7 cells, P < 0.01) and healthy
controls (superficial dermis: 0.8 ± 0.4 cells; deep dermis:
0.6 ± 0.5 cells, P < 0.01, Figure 2A, B). The infiltration of
Foxp3+ cells in the epidermis of lesional skin of early
SSc patients (6.5 ± 1.2 cells) was significantly greater
than the number observed in skin from late SSc patients
(2.2 ± 1.5 cells, P < 0.01) and healthy controls (1.0 ± 0.7
cells, P < 0.01; Figure 2C, D). The infiltration of Foxp3+
cells in the superficial and deep dermis of early SSc
patients (superficial dermis: 10.5 ± 1.6 cells; deep dermis:
Figure 2 Increased infiltration of IL-17+ and Foxp3+ cells in the skin of patients with active SSc. (A) IL-17 protein expression in superficial
dermis and deep dermis of early SSc patients examined by immunohistochemical staining. (B) Counts of IL-17+ lymphocytes in skin of SSc patients
(early SSc patients, n = 8; late SSc patients, n = 5). The positive cells in surface were counted under × 400 magnification, and five randomly selected
independent microscopic fields were counted for each sample to ensure that the data were representative and homogeneous. (C) Foxp3 protein
expression in epidermis, superficial dermis, and deep dermis of patients with early SSc examined with immunohistochemical staining (left panels).
Further magnification of the black-bordered box shows typical Foxp3+ lymphocytes (right panels). (D) Counts of Foxp3+ lymphocytes (×400 magnification)
in skin of SSc patients (early SSc patients, n= 8; late SSc patients, n= 5). The positive cells in surface were counted under × 400 magnification, and five
randomly selected independent microscopic fields were counted for each sample to ensure that the data were representative and homogeneous. Scale
bar, 100 μm.
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patients with late SSc (superficial dermis: 2.2 ± 1.3 cells;
deep dermis: 1.2 ± 0.8 cells, P < 0.01) and healthy con-
trols (superficial dermis: 0.8 ± 0.4 cells; deep dermis:
0.8 ± 0.4 cells, P < 0.01). These data suggest that both
IL-17+ and Foxp3+ lymphocytes might be involved in
the inflammation course of early SSc.The percentage of Th17 cells is expanded in SSc patients,
but the percentage of Treg cells is not significantly
affected
To investigate further these lymphocyte subgroups in
PBMCs of SSc patients, we studied 45 patients with SSc,
including 13 patients with active SSc and 32 with stable
SSc. Twenty-four age- and sex-matched healthy individuals
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CD3+CD8-IL-17+ Th17 cells measured with flow cy-
tometry (Figure 3A) was significantly increased in patients
with active SSc (2.14 ± 0.89%, n = 13) compared with those
with stable SSc (0.7 ± 0.34%, n = 32) and healthy controls
(0.57 ± 0.49%, n = 24; Figure 3B). We next questioned
whether the percentage of Th17 cells within the same
individual varied in relation to disease status. Ten in-
dividuals who were tested longitudinally showed aFigure 3 Expansion of Th17 cells in PBMCs of patients with active SSc
(anti-CD3 and -CD8). IL-17-expressing cells were detected by intracellular cyto
T cells was determined with flow cytometry. (B) Results of flow-cytometric an
SSc (n = 32), and controls (n = 24). (C) Longitudinal monitoring of Th17 cells in
active SSc and again after resolution after treatment. (D) Real-time RT-PCR ana
of patients with active SSc (n = 13), patients with stable SSc (n = 32), and cont
and clinical severity in active SSc patients, scored by using the Valentini score
+CD25+CD127- Treg cells in patients with active SSc (n = 13), patients with stadecrease in the percentage of Th17 cells after treatment
(1.31% ± 0.67% before treatment versus 0.78% ± 0.25%
after treatment, P < 0.05, Figure 3C). IL-17 is a key Th17-
derived cytokine that promotes the inflammatory responses
[26], and RORγt is a transcription factor that is expressed
in Th17 cells [27]. Both of these genes were highly
expressed in samples from patients with active SSc com-
pared with samples from healthy individuals and patients
with stable SSc (Figure 3D). Furthermore, comparison of. (A) Human PBMCs were labeled with antibody against lymphocytes
kine staining assay, and the percentage of IL-17+ cells among CD3+CD8-
alysis of Th17 cells in patients with active SSc (n = 13), patients with stable
10 patients. The percentage of Th17 cells was measured initially during
lysis of IL-17, Foxp3, and RORγt mRNA expression in freshly isolated PBMCs
rols (n = 24). (E) Positive correlation between the proportion of Th17 cells
(n = 13). r = 0.675, P < 0.01. (F) Results of flow cytometric analysis of CD4
ble SSc (n = 32), and controls (n = 24).
Yang et al. Arthritis Research & Therapy 2014, 16:R4 Page 7 of 11
http://arthritis-research.com/content/16/1/R4the percentage of Th17 cells with respect to disease acti-
vity revealed a positive correlation between the percentage
of Th17 cells and SSc activity characterized by Valentini
score (R = 0.675; P < 0.01; Figure 3E). These results imply
that Th17 cells might be involved in the SSc disease
process.
Treg cells play a key role in peripheral immune
tolerance and prevent the occurrence of autoimmune
disease [13,14]. In this study, Treg cells were quanti-
fied by CD4+CD25+CD127- T cells [12]. The percen-
tage of CD4+CD25+CD127- T cells decreased slightly, but
not significantly, in patients with active SSc (6.25 ± 1.22%,
n = 13) compared with patients with stable disease (6.47 ±
1.49%, P > 0.05, n = 32) and healthy controls (7.14 ± 1.61%,
P > 0.05, n = 24; Figure 3F). The percentage of Treg cells
was not related to disease activity and the expansion of
Th17 cells in patients with active SSc (data not shown).
Expression of Foxp3, a transcription factor in Treg cells,Figure 4 IL-17 derived from SSc patients induces collagen production
SSc (n = 13), patients with stable SSc (n = 32), and healthy controls (n = 24). (B
(n = 6), and healthy controls (n = 6) were stimulated for 5 hours with PMA and
(C) Fibroblasts were stimulated for 48 hours with supernatants from cultures o
from cultures of PI-stimulated PBMCs from patients with active SSc (Active), a
and collagen 3 was measured by real-time RT-PCR analysis. Results shown are
were stimulated for 48 hours with supernatants from cultures of PI-stimulated
PI-stimulated PBMCs from patients with active SSc (Active), and neutralization
supernatants were determined with ELISA. Results shown are representative owas not significantly different in patients with active SSc
compared with patients with stable disease and healthy
controls (Figure 3D).
Th17-derived IL-17 contributes to fibroblast proliferation
and collagen production
IL-17 secretion in serum was significantly increased in pa-
tients with active SSc (35.9 ± 4.7, n = 13) compared with
those with stable SSc (10.5 ± 2.6, P < 0.01, n = 32) and
healthy controls (8.1 ± 2.0, P < 0.05, n = 24; Figure 4A).
These data were consistent with a previous report that cir-
culatory IL-17 levels are increased in SSc patients [8]. We
further showed that IL-17 secretion from stimulated
PBMCs of patients with active SSc was increased com-
pared with PBMCs from patients with stable SSc and
healthy controls (Figure 4B).
We found that IL-17 alone could promote fibroblast
growth as measured by MTT assay (See Additional file 1:in fibroblasts. (A) IL-17 concentration in sera of patients with active
) PBMCs from patients with active SSc (n = 6), patients with stable SSc
ionomycin, and IL-17 in the supernatant was measured with ELISA.
f PI-stimulated PBMCs from healthy controls (Control) or, supernatants
nd neutralization of IL-17 (α-IL-17), and the gene expression of collagen 1
representative of at least three independent experiments. (D) Fibroblasts
PBMCs from healthy controls (Control) or, supernatants from cultures of
of IL-17 (α-IL-17), and the levels of collagen 1 and collagen 3 in the
f at least three independent experiments.
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and collagen 3 mRNA expression in fibroblasts in a dose-
dependent manner (See Additional file 1: Figure S1B).
These data indicated that IL-17 could induce fibroblast
growth and collagen production. To determine further
whether IL-17 derived from patients with active SSc can
induce fibroblast growth and collagen production, we pre-
pared supernatants from stimulated PBMCs of patients
with active SSc in culture, and investigated its effect on
the expression of collagen 1 and collagen 3 in fibroblasts.
We found that culture supernatants from PBMCs of pa-
tients with active SSc promoted both mRNA expression
and protein secretion of collagen 1 and collagen 3 in fi-
broblasts (Figure 4C, D). More notably, neutralization of
IL-17 in the culture medium inhibited mRNA expression
and protein secretion of collagen 1 and collagen 3
(Figure 4C, D). Furthermore, our data showed that super-
natants from stimulated PBMCs of active SSc patients
could dose- and time-dependently induce the collagen 1
and collagen 3 mRNA (See Additional file 2: Figure S2).Figure 5 Th17 cells contribute to fibroblast proliferation and collage
supernatants from cultures of PI-stimulated Th17 cells from patients with activ
IL-17-neutralizing antibody, and the gene expression of collagen 1 and collage
(B) Fibroblasts were stimulated for 48 hours with supernatants from cultures o
controls (Control) in the presence or absence of IL-17-neutralizing antibody, a
determined with ELISA (n = 5 for each group).These data indicate that fibroblasts are responsive to
stimulation by IL-17 produced by PBMCs derived from
SSc patients.
Although IL-17 derived from patients with active SSc
could induce fibroblast growth and collagen production,
it is not clear whether isolated Th17 cells have a similar
effect. To determine whether Th17 cells from patients
with active SSc induce collagen production in fibro-
blasts, CD4+CD161+CD196+ Th17 cells were sorted
from PBMCs of SSc patients and healthy controls, and
stimulated with PMA and ionomycin for 5 hours. The
supernatants were collected and cocultured with fibro-
blasts. Our data showed that isolated Th17 cells from
SSc patients produced more IL-17 than that of healthy
controls (data not shown). Furthermore, we showed that
supernatants from Th17 cells of patients with active SSc
induced more collagen 1 and collagen 3 production in
fibroblasts than did supernatants of Th17 cells from
healthy controls (Figure 5A, B), and neutralization of
IL-17 in the culture medium inhibited mRNA expressionproduction. (A) Fibroblasts were stimulated for 48 hours with
e SSc (Active) or healthy controls (Control) in the presence or absence of
n 3 was analyzed with real-time RT-PCR analysis (n = 5 for each group).
f PI-stimulated Th17 cells from patients with active SSc (Active) or healthy
nd the levels of collagen 1 and collagen 3 in the supernatants were
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gether, these data show that Th17 cell-derived IL-17
from SSc patients could promote fibroblast growth and
collagen production.
In addition, IL-17 not only induced collagen secretion,
but our data also showed that IL-17 could promote the
collagen synthesis (See Additional file 3: Figure S3A). Fur-
ther data showed that IL-17 could promote ERK phospho-
rylation in fibroblast, and ERK phosphorylation inhibitor
could block IL-17-iduced fibroblast proliferation and colla-
gen production (See Additional file 3: Figure S3B, C).
These data suggest that the ERK signal pathway might be
involved in the IL-17-mediated fibrosis in SSc patients.
Discussion
The pathologic hallmark of SSc is excessive collagen
deposition and microvascular injury. However, the me-
chanisms that lead to these changes remain largely
unknown. An early skin mononuclear cell infiltrate con-
sisting primarily of T cells and macrophages has been
demonstrated [28]. Moreover, the degree of mono-
nuclear cell infiltration in the skin of patients with SSc
has been shown to correlate well with both the degree
and progression of skin thickening [28]. Several lines of
evidence suggest that T cells are important in the patho-
genesis of SSc: first, T cells infiltrate skin early, before
any evidence of fibrosis; second, an increased number of
activated T cells is found in blood and skin lesions; third,
T cells producing cytokines can induce fibroblast colla-
gen production; fourth, T cells are necessary for antibody
production; and fifth, treatments directed against T cells
ameliorate systemic sclerosis [3]. These results bring the
role of T cells in the pathogenesis of SSc to the forefront
of the various mechanisms that may contribute to the
pathogenesis of the disease. Although the role of im-
mune dysfunction in the pathogenesis of SSc is generally
accepted and strong evidence exists for the participation
of T cells in the pathogenesis of this disease, the tra-
ditional Th1/Th2 paradigm has not been very helpful in
explaining several aspects of the illness.
In our study, we showed that patients with active SSc
had increased levels of circulating Th17 cells. In keeping
with these observations, Th17 cell–derived IL-17 was
significantly higher in the serum of SSc patients com-
pared with controls. In addition, increased infiltration of
IL-17+ cells was present in involved skin of patients with
early SSc. These data imply that Th17 cells are globally
expanded in patients with active SSc rather than being
redistributed. Although Th17 cells have been reported to
account for several autoimmune diseases [29-31], the role
of these cells in the course of fibrosis of SSc is not clearly
understood. Our data showed that IL-17 alone could in-
duce fibroblast growth and collagen gene expression and
protein secretion, IL-17 derived from PBMCs and Th17cells of patients with active SSc could promote collagen
gene expression and protein production in fibroblasts, and
neutralization of IL-17 in vitro could block collagen pro-
duction. Furthermore, Th17 cells isolated from active SSc
could promote fibroblast growth and collagen production.
IL-17 not only induced collagen secretion, but promote
fibroblast proliferation and the collagen synthesis (See
Additional file 3: Figure S3). These data indicate that
Th17 cell-derived IL-17 may be involved in the fibrosis of
SSc patients.
Treg cells are critical in maintaining self-tolerance and
preventing autoimmunity [13,14] and have been impli-
cated in the pathogenesis of several autoimmune diseases
[32]. Our previous study also showed that Treg cells were
depleted in patients with active SLE, which might be re-
lated to the expansion of Th17 cells [12]. In SSc patients,
some reports have shown that although the number of
Treg cells is markedly increased [4,33], these Treg cells
have a diminished capacity to control CD4 effector T cells
[34]. Our study showed that the number of circulating
Treg cells decreased slightly, but not significantly, in pa-
tients with active SSc, which is partially consistent with
previous findings that the percentage of Treg cells is de-
creased in SSc patients [21]. Treg cells dynamically change
with the development of disease activity, and the enrol-
ment of SSc patients with different disease activities might
contribute to the discrepancy in the percentage of Treg
cells among different studies. A major limitation of previ-
ous studies was that they did not determine whether Treg
cells infiltrated the skin of patients with different stage of
SSc, and the numbers of Treg cells that localized with
skin inflammation was not clear. Our study showed that
Foxp3+ Treg cells could be detected more frequently in
both the epidermis and dermis of patients with early SSc
compared with patients with stable SSc and healthy
controls. Our unpublished data showed that the isolated
circulating Treg cells did not affect fibroblast growth and
collagen production. The upregulation of Foxp3+ cells in
the skin of patients with early SSc may reflect a regulatory
feedback mechanism to restore cellular tolerance and
ameliorate harmful autoimmune responses.
One of the strengths of this study is the ability to analyze
inflammatory cell subsets in involved skin of SSc patients
with different clinical stages of disease. This enabled us to
evaluate which complex inflammatory cell groups might be
dynamically involved in the pathogenesis of SSc. Our data
showed that Th17 cells were globally expanded in patients
with active SSc and that Th17 cell-derived IL-17 might be
related to the fibrosis of SSc. Further studies into the role
of Th17 cells and IL-17 in fibrosis, as well as their effects in
affected cells and tissue, are warranted. Furthermore, Th17
cell are only one of the factors for the fibrosis in SSc; more
study should be done to make clear other lymphocytes or
cytokines in the pathogenesis of fibrosis of SSc.
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Taken together, our data suggest that the pathophy-
siology of SSc might be linked to the expansion of Th17
cells and that Th17-derived IL-17 may play a key role in
the fibrotic course of SSc. These insights open novel av-
enues for research aimed at identifying pathogenic path-
ways and therapeutic targets.
Additional files
Additional file 1: Figure S1. IL-17 induces fibroblast proliferation and
collagen production. (A) Fibroblasts isolated from SSc patients were
cultured in 20 ng/ml IL-17 or vehicle for the indicated number of days,
and their growth was analyzed by MMT assay. (B) Fibroblasts were
cultured in the indicated doses of IL-17 for 48 hours; the gene expression
of collagen 1 and collagen 3 was measured by real-time RT-PCR analysis.
Additional file 2: Figure S2. IL-17 derived from SSc patients induces
collagen gene expression in fibroblasts. (A) Fibroblasts were stimulated
with different concentrations of supernatants of PI-stimulated PBMCs
from patients with active SSc (Active) and PI-stimulated PBMCs from
healthy controls (Control) for 48 hours, and the gene expression of
collagen 1 and collagen 3 was measured by real-time RT-PCR analysis.
(B) Fibroblasts were stimulated with supernatants of PI-stimulated PBMCs
from patients with active SSc (Active) and PI-stimulated PBMCs from
healthy controls (Control) for different hours, and the gene expression of
collagen 1 and collagen 3 was measured by real-time RT-PCR analysis.
Results shown are representative of at least three independent
experiments.
Additional file 3: Figure S3. ERK activation is involved in the IL-17-
mediated fibroblast proliferation and collagen production. (A) Fibroblast
was stimulated with indicated doses of IL-17 in the presence or absence
of IL-17 neutralizing antibody for 24 hours; collagen-1 and collagen-3
protein expressions in fibroblast were analyzed with Western blot.
(B) Fibroblast was stimulated with IL-17 and different doses of
ERK- specific phosphorylation inhibitor-PD98059 for 24 hours; collagen-1
and collagen-3 protein expressions in fibroblast were analyzed with
Western blot. (C) Fibroblast was stimulated with IL-17 and ERK specific
phosphorylation inhibitor-PD98059 for indicated days, the proliferation
of fibroblast was examined by cell counting kit-8.
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